可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:
[1] Resnic FS, Wainstein M, Lee MK, et al. No-reflow is an independent predictor of death and myocardialinfarction after percutaneous coronary intervention[J]. Am Heart J, 2003, 145(1):42-46.
[2] Morishima I, Sone T, Okumura K, et al. Angographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients trested with percutaneous transluminial angioplasty for first acute myocardial infarction[J]. J Am Coll Cardiol, 2000, 36(4):1202-1209.
[3] Marzilli M, Orsini E, Marraccini P, et al. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction [J]. Circulation, 2000, 101(18):2154-2159.
[4] Gibson CM, Cannon CP, Daley WL, et al. TIMI frame count: a quantitative method of assessing coronary artery flow[J]. Circulation, 1996, 93(5):879-888.
[5] 胡波,来庆友,商德亚. 缺血/再灌注后心肌微循环障碍研究[J]. 心脏杂志, 2005, 17 (1):81-82.
[6] Iwakura A, Ito H, Kawano S, et al. Chronic pre-treatment of statins is associated with the reduction of the no-reflow phenomenon in the patients with reperfused acute myocardial infarction[J]. Eur Heart J, 2006, 27(5):534-539.
[7] Hamada S, Nishiue T, Nakamura S, et al. TIMI frame count immediately after primary coronary angioplasty as a predictor of functional recovery in patients with TIMI 3 reperfused acute myocardial infarction[J]. J Am Coll Cardiol, 2001, 38(3):666-671.
[8] Lim SY, Bae EH, Jeong MH, et al. Effect of combined intracoronary adenosine and nicoranil on no-reflow phenomenon during percutaneous coronary intervention[J]. Circ J, 2004, 68(10):928-932.
[9] 赵季红,侯允天,张利华. 冠心病与炎症的关系以及C 反应蛋白新的临床意义[J]. 心脏杂志, 2001, 13(5):398-400.
[10]吴兆增,李梅,骆美瑛,等. 冠心病患者血清hs-CRP和M-CSF检测的临床意义[J]. 放射免疫学杂志, 2006, 19(4):291-292.
[11]杨春秀. 冠心病患者血清hs-CRP和E-Selectin检测的临床意义[J]. 放射免疫学杂志, 2007, 20(3):276-277.
[12]Mangoni ME, Barrère-Lemaire S. Adenosine receptors, heartrate, and cardioprotection[J]. Cardiovasc Res, 2004, 62(3):447-449.